SWOT Analysis for Trevi Therapeutics Inc

Price crossing above SMA20 today, and greater than SMA5
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with 10% increase in share price over three months, with rising net profit growth
Consistent Highest Return Stocks over Five Years
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Relative Outperformance versus Industry over Half Year (6 Months)
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
MACD crossed above zero line previous end of day
Companies with Low Debt
Increasing profits every quarter for the past 2 quarters
Top Gainers
Stock with Low PE (PE < = 10)
Volume Shockers
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter

PEG greater than Industry PEG
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Book Value Per Share deteriorating for last 2 years

Forecaster Consensus Estimates: Stocks with Strong Buy Calls from Analysts
Mutual Funds Increased Shareholding in Past Month
Institutions increasing their shareholding
Mutual Funds Increased Shareholding over the Past Two Months
MFs increased their shareholding last quarter
Mf buying for 2 months